Molecular mechanisms in evolutionary cardiology failure

被引:19
|
作者
Swynghedauw, Bernard [1 ]
Delcayre, Claude
Samuel, Jane-Lyse
Mebazaa, Alexandre [2 ]
Cohen-Solal, Alain [1 ]
机构
[1] Hop Lariboisiere, INSERM, U942, Dept Cardiol, F-75475 Paris 10, France
[2] Hop Lariboisiere, Dept Anesthesiol, F-75475 Paris, France
来源
ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE | 2010年 / 1188卷
关键词
heart failure; cardiac hypertrophy; microRNA; fibrosis; fetal hypothesis; wall stress hypothesis; Laplace's law; aldosterone; evolution; Darwinian or evolutionary medicine; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; HEART-FAILURE; PRESSURE-OVERLOAD; PHENOTYPIC PLASTICITY; ALDOSTERONE; RAT; CARDIOMYOPATHY; TRANSCRIPTOME; MICROARRAY;
D O I
10.1111/j.1749-6632.2009.05084.x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Integration of the relevant evolutionary paradigm in cardiology has not yet been fully achieved: In the past, heart failure (HF) was mainly ascribed to infections, and the origins of cardiac hypertrophy (CH) were regarded as mechanical. Recent changes in lifestyle have both reduced the incidence of infections and increased lifespan, and H F is now seen as a complex disease one that is still caused by mechanical disorder, but also associated with ischemia and senescence. The long-held view that CH serves to restore myocardial economy back to normal is still valid. The adaptive process is characterized by a quantitative and a qualitative fetal gene reprogramming, which is now being confirmed by recent advances in microRNA research. It underscores the fact CH is the physiologic reaction of the heart to a pathologic stimulus. The goal for therapy is economic, not inotropic. Another major issue is myocardial fibrosis, a major determinant of diastolic function and arrhythmias. Recent changes in lifestyle have crucially modified the context in which HF occurs.
引用
收藏
页码:58 / 67
页数:10
相关论文
共 50 条
  • [21] Matricellular Proteins: New Molecular Targets To Prevent Heart Failure
    Okamoto, Hiroshi
    Imanaka-Yoshida, Kyoko
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (04) : e198 - e209
  • [22] New directions in basic research in hypertrophy and heart failure: Relevance for pediatric cardiology
    Bernstein, Daniel
    Webber, Steven
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2011, 32 (01) : 5 - 9
  • [23] A simplified herbal formula for the treatment of heart failure: Efficacy, bioactive ingredients, and mechanisms
    Chen, Zixin
    Luo, Tong
    Zhang, Lu
    Zhou, Zheng
    Huang, Yusheng
    Lu, Lu
    Yang, Zhongqi
    Wang, Lingjun
    Xiang, Shaoxiang
    PHARMACOLOGICAL RESEARCH, 2019, 147
  • [24] Molecular mechanisms of diabetic cardiomyopathy
    Bugger, Heiko
    Abel, E. Dale
    DIABETOLOGIA, 2014, 57 (04) : 660 - 671
  • [25] Molecular mechanisms of diabetic cardiomyopathy
    Heiko Bugger
    E. Dale Abel
    Diabetologia, 2014, 57 : 660 - 671
  • [26] CELLULAR AND MOLECULAR MECHANISMS IN HEART-FAILURE
    KRAUSE, EG
    ZEITSCHRIFT FUR KARDIOLOGIE, 1991, 80 : 13 - 18
  • [27] Molecular mechanisms and clinical features of heart failure
    Suzuki, Satoshi
    Takeishi, Yasuchika
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2018, 64 (03) : 116 - 124
  • [28] Molecular mechanisms underlying sarcopenia in heart failure
    Rutledge, Cody A.
    JOURNAL OF CARDIOVASCULAR AGING, 2024, 4 (01):
  • [29] The Effect of Resveratrol on the Cardiovascular System from Molecular Mechanisms to Clinical Results
    Gal, Roland
    Deres, Laszlo
    Toth, Kalman
    Halmosi, Robert
    Habon, Tamas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [30] Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms
    Hedayati, Neda
    Yaghoobi, Alireza
    Salami, Marziyeh
    Gholinezhad, Yasaman
    Aghadavood, Farnaz
    Eshraghi, Reza
    Aarabi, Mohammad-Hossein
    Homayoonfal, Mina
    Asemi, Zatollah
    Mirzaei, Hamed
    Hajijafari, Mohammad
    Mafi, Alireza
    Rezaee, Malihe
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10